The creation and launch of products with cutting-edge features and technology is being facilitated by the major companies’ persistent efforts as well as the growing demand for innovative items. To create effective diagnostic tests, major market participants have shifted their attention to implementing cutting-edge technologies like machine learning, IoT, and artificial intelligence. Elecsys HBeAg quant, an immunoassay that measures the quantity and presence of the hepatitis Be antigen (HBeAg) in human serum and plasma, was introduced by F. Hoffmann-La Roche Ltd. in November 2023.
Thanks to technical improvements, POC testing instruments now have additional capabilities including improved mobility and miniaturization. Bioassays including polymerase chain reaction (PCR), enzyme-linked immunosorbent assays (ELISA), and microbiological culture can now be employed at the point of care thanks to technological improvements. Using a special and exclusive microfluidic technology, Sysmex Corporation introduced a point-of-care testing device for the quick identification of antibiotic susceptibility in Europe in June 2023.
Therefore, it is anticipated that the market’s players’ increased focus on research and development (R&D) as well as the growing initiatives of national and international healthcare organizations and government bodies to raise awareness about testing for various chronic conditions will spur technological advancements in the products.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Point of Care Diagnostics Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Point of Care Diagnostics Market details, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
Point of Care Diagnostics Market based on Product:
- Blood Glucose Monitoring
- Infectious Disease Testing
- Cardiometabolic Disease Testing
- Pregnancy & Fertility Testing
- Hematology Testing
- Others
Point of Care Diagnostics Market based on Sample:
- Blood
- Nasal and Oropharyngeal Swabs
- Urine
- Others
Point of Care Diagnostics Market based on End User:
- Hospital Bedside
- Physician’s Office Lab
- Urgent Care & Retail Clinics
- Home & Self testing
Point of Care Diagnostics Market based on Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
The market is divided into segments based on product, including hematological testing, infectious disease testing, cardiometabolic disease testing, blood glucose monitoring, and pregnancy and fertility testing.
In 2023, the sector that led the worldwide point of care diagnostics market share was blood glucose monitoring. The increasing number of people with diabetes and the industry’s increasing emphasis on creating and releasing goods with cutting-edge features and technology are some of the key drivers of the segment’s expansion. Dexcom, Inc. introduced Dexcom ONE+, the most recent Continuous Glucose Monitoring (CGM), in February 2024 with the goal of providing patients in the Netherlands with effective, cutting-edge diabetes care technology.
Over the course of the projection period, the pregnancy and fertility testing segment is expected to develop at a high rate. The increasing prevalence of sexual health knowledge and fertility problems can be credited for the segment’s growth. The increasing use of diverse testing kits and products, particularly in developed nations like the United States, Germany, and the United Kingdom, is a significant factor driving the expansion of this market.
The growing prevalence of various infectious diseases and chronic conditions like HIV and cancer, among others, as well as the higher rate of screening and early diagnosis of these conditions, among other factors, are among the reasons why the hematology testing, infectious disease testing, and other segments are expected to grow during the forecast period.
The market is segmented based on sample type, including urine, nasal and oropharyngeal swabs, blood, and others.
During the projection period, the blood sector is anticipated to increase at a considerable compound annual growth rate (CAGR) and maintain its dominant market position as of 2023. Blood tests can assist medical professionals in correctly diagnosing patients for a number of illnesses, such as coronary artery disease, HIV/AIDS, and problems with the kidney, liver, and thyroid. Therefore, the use of blood tests for a variety of disease diagnoses and their effectiveness in doing so have been driving the segment’s rise.
Due to the rising prevalence of kidney-related illnesses in the population, the urine segment is anticipated to increase at a considerable compound annual growth rate (CAGR) over the forecast period.
The point of care diagnostics market is divided into four end-user segments based on location: hospital bedside, doctor’s office lab, urgent care & retail clinics, and home & self-testing.
In 2023, the market was dominated by the hospital bedside sector. Some of the key factors driving the growth of the market segment include the increasing use of sophisticated POC testing instruments and devices in hospitals in developed nations, advancements in healthcare infrastructure, and increased investments by the public and private sectors in emerging nations due to rising healthcare costs in these nations.
The point-of-care diagnostics market is split into the following regions: Asia Pacific, Europe, North America, Middle East & Africa, and Latin America.
Furthermore, over the course of the projection period, Asia Pacific is anticipated to grow at a notable CAGR. Point-of-care diagnostic test usage is expected to be accelerated by the region’s rising incidence of infectious diseases and chronic illnesses. The Japanese release of a test kit to detect amyloid beta accumulation in the brain, a contributing factor to Alzheimer’s disease, was announced by Sysmex Corporation in June 2023.
- This report illustrates the most vital attributes of the Point of Care Diagnostics Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Point of Care Diagnostics Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Point of Care Diagnostics Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Point of Care Diagnostics Market.
List of Tables
TABLE 1. POINT OF CARE DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR BLOOD GLUCOSE MONITORING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR INFECTIOUS DISEASE TESTING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR CARDIOMETABOLIC DISEASE TESTING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR PREGNANCY & FERTILITY TESTING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR HEMATOLOGY TESTING, 2021-2030 (USD BILLION)
TABLE 7. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. POINT OF CARE DIAGNOSTICS MARKET VALUE, BY SAMPLE, 2021-2030 (USD BILLION)
TABLE 9. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR BLOOD, 2021-2030 (USD BILLION)
TABLE 10. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR NASAL AND OROPHARYNGEAL SWABS, 2021-2030 (USD BILLION)
TABLE 11. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR URINE, 2021-2030 (USD BILLION)
TABLE 12. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. POINT OF CARE DIAGNOSTICS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 14. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR HOSPITAL BEDSIDE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 15. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR PHYSICIAN’S OFFICE LAB, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR URGENT CARE & RETAIL CLINICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 17. POINT OF CARE DIAGNOSTICS MARKET VALUE FOR HOME & SELF TESTING, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 19. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 20. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 21. NORTH AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 22. U.S POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 23. U.S POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 24. U.S POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 25. U.S POINT OF CARE DIAGNOSTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION)
TABLE 26. CANADA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 27. CANADA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 28. CANADA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 29. MEXICO POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 30. MEXICO POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 31. MEXICO POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 32. EUROPE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 33. EUROPE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 34. EUROPE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 35. EUROPE POINT OF CARE DIAGNOSTICS MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION)
TABLE 36. GERMANY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 37. GERMANY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 38. GERMANY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 39. U.K POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 40. U.K POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 41. U.K POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 42. FRANCE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 43. FRANCE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 44. FRANCE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 45. ITALY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 46. ITALY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 47. ITALY POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 48. SPAIN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 49. SPAIN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 50. SPAIN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 51. ROE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 52. ROE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 53. ROE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 54. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 55. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 56. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 57. ASIA PACIFIC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 58. CHINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 59. CHINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 60. CHINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 61. INDIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 62. INDIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 63. INDIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 64. JAPAN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 65. JAPAN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 66. JAPAN POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 67. REST OF APAC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 68. REST OF APAC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 69. REST OF APAC POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 70. LATIN AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 71. LATIN AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 72. LATIN AMERICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 73. BRAZIL POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 74. BRAZIL POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 75. BRAZIL POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 76. ARGENTINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 77. ARGENTINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 78. ARGENTINA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 79. MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 80. MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 81. MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 82. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 83. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 84. SAUDI ARABIA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 85. UAE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 86. UAE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 87. UAE POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 88. REST OF MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CONNECTIVITY TYPE, 2021-2030 (USD BILLION)
TABLE 89. REST OF MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY RESOLUTION, 2021-2030 (USD BILLION)
TABLE 90. REST OF MIDDLE EAST AND AFRICA POINT OF CARE DIAGNOSTICS MARKET VALUE, BY CAMERA TYPE, 2021-2030 (USD BILLION)
TABLE 91. CARDINAL HEALTH INC.: FINANCIALS
TABLE 92. CARDINAL HEALTH INC.: PRODUCTS & SERVICES
TABLE 93. CARDINAL HEALTH INC.: RECENT DEVELOPMENTS
TABLE 94. TRINITY BIOTECH: FINANCIALS
TABLE 95. TRINITY BIOTECH: PRODUCTS & SERVICES
TABLE 96. TRINITY BIOTECH: RECENT DEVELOPMENTS
TABLE 97. BIO-RAD LABORATORIES INC.: FINANCIALS
TABLE 98. BIO-RAD LABORATORIES INC.: PRODUCTS & SERVICES
TABLE 99. BIO-RAD LABORATORIES INC.: RECENT DEVELOPMENTS
TABLE 100. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
TABLE 101. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
TABLE 102. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
TABLE 103. QUEST DIAGNOSTICS INCORPORATED: FINANCIALS
TABLE 104. QUEST DIAGNOSTICS INCORPORATED: PRODUCTS & SERVICES
TABLE 105. QUEST DIAGNOSTICS INCORPORATED: RECENT DEVELOPMENTS
TABLE 106. QUIDEL CORPORATION: FINANCIALS
TABLE 107. QUIDEL CORPORATION: PRODUCTS & SERVICES
TABLE 108. QUIDEL CORPORATION: RECENT DEVELOPMENTS
TABLE 109. ABBOTT LABORATORIES: FINANCIALS
TABLE 110. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 111. ABBOTT LABORATORIES: DEVELOPMENTS
TABLE 112. MESA BIOTECH: FINANCIALS
TABLE 113. MESA BIOTECH: PRODUCTS & SERVICES
TABLE 114. MESA BIOTECH: RECENT DEVELOPMENTS
TABLE 115. F. HOFFMANN-LA ROCHE LTD: FINANCIALS
TABLE 116. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 117. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 118. CEPHEID: FINANCIALS
TABLE 119. CEPHEID: PRODUCTS & SERVICES
TABLE 120. CEPHEID: RECENT DEVELOPMENTS
